S Korean biotech firm clones cancer-sniffing dogs
A South Korean biotech firm announced it has successfully cloned four dogs capable of sniffing out human cancers by using tissue from a Labrador retriever in Japan, media reported Wednesday.
RNL Bio, a leader in commercializing cloning in South Korea, said Monday the dogs were born last month and would be sent to Japan for training in the same skills as their mother. Two of them will later be sold to clients at 500 million won (480,000 U.S. dollars) each or more, it said.
The cloning, requested by the Japanese stemcell company Seems, was conducted by a team led by Seoul National University professor Lee Byeong-Chun and has been verified by the medical school.
